Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has submitted the Exchange a copy of the Srutinizers report of the Annual General Meeting held on September 29, 2026. The company has informed the Exchange regarding voting results.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has held its 34th Annual General Meeting on September 29, 2026, through video conferencing. The meeting was attended by all directors, the chairman, and other officials. The company has provided electronic voting facility to its members, and the results of the voting will be declared after the report of the scrutinizer is received.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has informed the Exchange regarding the closure of the trading window for insiders due to the upcoming announcement of unaudited financial results for the 2nd quarter and half year ended September 30, 2026.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 698.35 crores and a net loss of Rs. 248.48 crores.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has informed the Exchange about a copy of newspaper publication regarding the notice of 34th Annual General Meeting (AGM) of the company.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. prior intimation of 34th AGM of the Company.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication, which includes unaudited financial results for the 1st quarter ended June 30, 2026, and a notice regarding lost, destroyed, misplaced, or stolen share certificates.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has submitted its unaudited financial results for the 1st quarter ended June 30, 2026, to the Exchange, following a board meeting.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has informed the Exchange about Scheme of Arrangement with Ipca Laboratories Limited, where the former will be amalgamated into the latter. The amalgamation is subject to necessary approvals and will result in operational synergies, cost optimization, and increased business for the combined entity.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has approved a Scheme of Amalgamation with Ipca Laboratories Limited, subject to necessary approvals. The appointed date for the Scheme is 1st April, 2026, and the effective date will be upon receipt of all consents and approvals. The amalgamation will result in operational synergies, cost optimization, and an increased business for the combined entity.

Krebs Biochemicals and Industries Limited

Krebs Biochemicals and Industries Limited has announced the closure of its trading window for promoters, directors, designated persons, their immediate relatives, and connected persons. This closure is effective from the close of business hours on June 30, 2026, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the first quarter ended June 30, 2026. This measure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent insider trading ahead of the financial results.